Illumina aims to have its test on the market by 2019 and hopes the cost of DNA sequencing will have dropped enough to price the cancer screening test around $500 each, low enough to make it widely accessible, Flatley said. Several companies are developing liquid biopsies, mostly for use with patients already diagnosed with cancer. The hope is to detect many types of newly forming cancers, which could be treated at an earlier stage to increase the chances of survival.Ĭowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade. Grail’s test will use Illumina’s DNA sequencing technology to scan for bits of cancer genes originating in tumors and circulating in the bloodstream.
Key investors include ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Amazon founder Jeff Bezos.
GRAIL DNA SEQUENCE ANALYSIS SERIES
On Sunday, San Diego-based Illumina said it would form a new company, called Grail, with more than $100 million in Series A financing. CHICAGO, Jan 10 (Reuters) - Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease.
0 kommentar(er)
